Market Research Logo

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016’, provides in depth analysis on Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted pipeline therapeutics.

The report provides comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
    • The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Overview
Therapeutics Development
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Stage of Development
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Therapy Area
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Indication
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Companies
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development
Ampio Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Cyano Biotech GmbH
Lixte Biotechnology Holdings, Inc.
Signum Biosciences, Inc.
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles
Drugs to Activate PP2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-1154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PP2A for Parkinson Disease and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PP1 and PP2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEL-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Projects
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Featured News & Press Releases
Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity
Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds
Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies
Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer
Apr 25, 2013: Lixte Biotechnology Initiates Phase I Trial Of Its Lead Anti-Cancer Compound LB-100
Jul 31, 2012: Lixte Biotechnology Announces Increased Funding And FDA Allowance To Conduct Phase I Trial Of LB-100
Jul 16, 2012: Ampio Pharma Advances NCE001 Cancer Drug Into Preclinical Development
May 01, 2012: Lixte Submits Investigational New Drug Application To FDA For Approval Of Clinical Trial Of LB-100
Sep 22, 2011: Lixte Biotechnology Receives US Patent For LB-100
Oct 05, 2010: Lixte Collaborates With NCI For Clinical Evaluation Of LB-100
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
Pipeline by Bristol-Myers Squibb Company, H2 2016
Pipeline by Cyano Biotech GmbH, H2 2016
Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
Pipeline by Signum Biosciences, Inc., H2 2016
Dormant Projects, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report